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Abstract: 
Eight-week-old rats inhaled manganese (Mn) in the form of MnSO4 at 0, 0.03, 0.3, or 3.0 mg Mn/m
3
 for 6 h/d 
for 7 d/wk (14 consecutive exposures). Brain manganese concentrations in these animals were reported by 
Dorman et al. in 2001, noting the following rank order: olfactory bulb > striatum > cerebellum. We assessed 
biochemical end points indicative of oxidative stress in these three brain regions, as well as the hypothalamus 
and hippocampus. Glutamine synthetase (GS) protein levels and total glutathione (GSH) levels were determined 
for all five regions. GS mRNA and metallothionein (MT) mRNA levels were also evaluated for the cerebellum, 
hypothalamus, and hippocampus. Statistically significant increases (p<0.05) in GS protein were observed in the 
olfactory bulb upon exposure to the medium and high manganese doses. In the hypothalamus, statistically 
significant (p<0.05) but more modest increases were also noted in the medium and high manganese dose. Total 
GSH levels significantly (p<0.05) decreased only in the hypothalamus (high manganese dose), and MT mRNA 
significantly increased in the hypothalamus (medium manganese dose). No significant changes were noted in 
any of the measured parameters in the striatum, although manganese concentrations in this region were also 
increased. These results demonstrate that the olfactory bulb and hypothalamus represent potentially sensitive 
areas to oxidative stress induced by exceedingly high levels of inhaled manganese sulfate and that other regions, 
and especially the striatum, are resistant to manganese-induced oxidative stress despite significant accumulation 
of this metal. 
Index Entries: Manganese; rat; oxidative stress; inhalation, in vivo. 
 
Article: 
INTRODUCTION 
Manganese-induced neurotoxicity has been found among miners who inhale particulate matter containing 
manganese. The highest brain manganese levels in these individuals are found in globus pallidus, and there is 
concomitant neuronal loss in basal ganglia and associated nuclei (1–3). The impact of manganese (Mg) on 
human health and disease upon low-level chronic exposure to environmental manganese is uncertain. The 
manganese fuel additive methylcyclopentadienyl manganese tricarbonyl (MMT) is combusted to yield a variety 
of manganese salts (4–6). The pharmacokinetics and brain accumulation of three MMT combustion products, 
namely, manganese phosphate (Mn5(PO4)2[(PO3)(OH)]2 · 4H2O), manganese sulfate (MnSO4), and manganese 
tetroxide (Mn3O4) were recently evaluated in rats inhaling 0, 0.03, 0.3, or 3 mg/m
3
 for 6 h/d on 14 consecutive 
days (7). The sulfate form of manganese was more efficiently cleared from the rats’ lungs and it accumulated at 
a higher rate in the olfactory bulb and striatum than did the phosphate or tetroxide (7). Thus, the rate of delivery 
of different forms of manganese to brain regions via inhalation depends, in part, on the solubility of the 
compounds. 
 
Oxidative stress has been implicated as a contributing mechanism by which manganese can be toxic to cells (8). 
A potential mechanism invoked for manganese-induced oxidative stress is via the oxidation of dopamine and 
other catecholamines (9). This is likely because manganese in primates accumulates in dopamine-rich regions, 
especially in the basal ganglia. Another possibility is that sequestration of manganese in mitochondria interferes 
with proper respiration, thereby leading to excessive production of reactive oxygen species. Galvani et al. (10) 
reported inhibition of complex I of the electron transport chain after treatment of PC12 cell cultures with 
MnCl2. Gavin et al. (11) showed evidence suggesting that the ATPase complex is inhibited at very low levels of 
mitochondrial manganese and that complex I is inhibited only at higher manganese concentrations. In 
agreement with the earlier suggestion of Archibald and Tyree (12) and the findings of Ali et al. (13), Chen et al. 
(14) demonstrated that trivalent manganese is more effective at inhibiting complex I, but the divalent form is, 
by far, the predominant species within cells and is largely bound to ATP. Nevertheless, manganese in any state 
will spontaneously give rise to infinitesimal amounts of trivalent manganese, and HaMai et al. (15) 
demonstrated that even at trace amounts trivalent manganese can cause the formation of reactive oxygen species 
(ROS). They also showed evidence that divalent manganese fails to induce oxidative effects. Finally, a recent 
report showed that exposure of dopaminergic cells to MMT resulted in rapid increases in reactive oxygen 
species followed by mitochondrially induced apoptosis (16). However, because combustion of MMT in cars 
yields various manganese salts and MMT is unstable in the air and groundwater, direct exposure of cells to 
MMT does not represent a toxicologically relevant experimental model for inorganic manganese. 
 
Manganese exposure studies do not always yield results consistent with induction of oxidative stress. 
Manganese administered orally to developing CD rats (0, 25, or 50 mg/kg/d of MnCl2 from postnatal day 
[PND] 1 to PND 49) was correlated with increased spontaneous motor activity on PND 21, but ROS levels were 
only elevated in the cerebellum and not in the striatum, the primary target site in primates (17). Addition-ally, 
experiments by Ball et al. (18) demonstrated that six metal com-pounds, including iron sulfate, copper sulfate, 
vanadyl sulfate, cobalt sulfate, nickel sulfate, and zinc sulfate, are able to form ROS (measured by 
malondialdehyde formation) in aqueous extracts of National Institute of Standards and Technology (NIST) 
ambient particulate matter and diesel engine particles. Manganese, however, did not. Furthermore, a study by 
Oubrahim et al. (19) confirmed that low cellular concentrations of divalent manganese are actually protective 
against oxidative stress. This is consistent with the well-known requirement for manganese as a cofactor for the 
mitochondrial superoxide dismutase enzyme, which has tremendous physiological antioxidant properties. 
 
We previously analyzed the end points of oxidative stress in brains of neonatal rats exposed orally to MnCl2 
(20). The susceptibility of neonatal animals to manganese neurotoxicity may be higher compared with adults 
because of the incomplete development of the blood–brain barrier and their inability to excrete manganese 
before weaning. However, the only significant oxidative difference noted in these animals was an increase in 
glutathione (GSH) levels in the cortex (20). Additionally, the manganese concentrations required for optimal 
central nervous system (CNS) development in neonatal rat brain are known to be higher than are found in adult 
rat brain (21) and, therefore, the interpretation of these data as evidence for increased susceptibility to 
manganese neurotoxicity is questionable. Blood concentrations of manganese are also threefold higher in 
neonatal rats than in adults, and this undoubtedly contributes to the higher level of manganese uptake into the 
brain (22,23). 
 
In contrast to the previous work, the present study was conducted in adult rats exposed to manganese by 
inhalation. After 14 consecutive days of manganese sulfate inhalation exposures, GSH, glutamine synthetase 
(GS) protein, and mRNA and metallothionein (MT) mRNA levels were measured in the cerebellum, striatum, 
olfactory bulb, hypothalamus, and hippocampus as indicators of potential oxidative stress in the brain. 
 
MATERIALS AND METHODS  
Chemicals 
Manganese(II) sulfate monohydrate (MnSO4 · H2O) was obtained from Aldrich Chemical Co. (Milwaukee, WI). 
Manganese sulfate is a relatively water-soluble, pale pink, crystalline powder that contains 32% manganese. All 
other chemicals were purchased from Sigma Chemical (St. Louis, MO) unless otherwise noted and were of the 
highest possible quality. 
 
 
Animals 
Dorman et al. (7) previously detailed animal treatments and exposures. The study was conducted under federal 
guidelines for the care and use of laboratory animals (24) and was approved by the CIIT Institutional Animal 
Care and Use Committee. Six-week-old male Crl : CD (SD)BR rats were purchased from Charles River 
Laboratories, Inc. (Raleigh, NC) and ear-tagged for identification purposes. Animals were acclimated for 
approx 2 wk in a HEPA-filtered, mass-air-displacement room maintained at 18.5–21.5°C and 40–60% relative 
humidity in CIIT’s AAALAC-accredited animal facility. Rats were individually housed in suspended stainless-
steel cages (Lab Products, Inc., Seaford, DE) with an automatic watering system that provided reverse-osmosis-
purified water ad libitum. Fluorescent lighting was kept on a 12-h light–dark cycle (0600–1800). A study day 
for these exposures was defined as a 6-h exposure, generally from 0830 to 1430. Animals were given NIH-07 
rodent chow (Zeigler Bros., Gradners, PA) ad libitum except during exposure times. Manganese concentrations 
in this diet are approx 100–150 ppm. 
 
At the end of the acclimation period, animals were randomly assigned to inhalation-treatment groups based on 
their prestudy body weight. Mean initial body weights within each treatment group were not statistically 
different. The animals (n = 12 rats/ concentration) were exposed to MnSO4 inhalation for 6 h/d, 7 d/wk for 14 
consecutive exposure days. 
 
Manganese Exposures 
Nominal exposure concentrations were 0.092, 0.92, and 9.2 mg MnSO4/m
3
, corresponding to 0.03, 0.3, and 3 
mg Mn/m
3
. Target nominal particle size (MMAD) was approx 1.5–2 pm with a geometric standard deviation 
(σg) <2. Control groups were exposed to HEPA-filtered air only. Rats were exposed in stainless-steel wire cage 
units contained within eight Hazelton 1-m
3
 stainless-steel and glass inhalation exposure chambers. Prior to the 
animals being placed in the 1-m
3
 chambers, each chamber was checked for uniformity of distribution of the test 
compound aerosol by measuring its concentration at nine positions within the chamber. Animal positions within 
the 1-m
3
 exposure chambers were rotated once during the experiment to minimize experimental error resulting 
from any undetected differences in the environment or manganese aerosol concentration. 
 
The airflow through each 1-m
3
 chamber was maintained at 200–250 L/min to provide 12–15 air changes per 
hour during the exposures. The temperature and humidity in each 1-m
3
 inhalation chamber was measured every 
30 min using a thermistor (PreCon, Memphis, TN) and a humidity probe (OMEGA Engineering, Inc., Stamford, 
CT). The temperature was maintained at a target of 22.2°C, and relative humidity was maintained at 30–70% 
with a target of 50%. 
 
The MnSO4 atmospheres were generated as a dry powder using a Wright Dust Feeder with an air-delivery 
pressure of 25 psi. The MnSO4 was packed into a Wright Dust Feeder generation cup at a pressure of 2000 psi. 
A Trost Airjet Mill (Garlock Corp., Newton, PA) was also required to generate the MnSO4 aerosol. The aerosol 
was delivered into stainless-steel prechambers (fitted with 
85
Kr discharging units) of approx 38-L that allowed 
settling of larger particles (>10 μm). The aerosol then went through a polyvinyl chloride distribution line tuned 
to allow equal residence times of particles in the pathway to each 1-m
3
 exposure chamber. The aerosol was 
diluted to the appropriate concentration in the inlet airstream to each 1-m
3
 inhalation chamber. The aerosol in 
the prechamber and in each 1-m
3
 inhalation chamber was monitored continuously using an optical particle 
sensor (Real-time Aerosol Monitor, Model RAM-S; MIE Inc., Bedford, MA) precalibrated for a standard dust 
(Arizona road dust). The average aerosol mass concentration was determined using gravimetric filter samples. 
Flow through the filter samplers was started 15 min after the beginning of the exposure and stopped at the end 
of the exposure. The filter sampler flow was controlled with critical flow orifices. The particle size distribution 
was measured with a time-of-flight aerosol spectrometer (TSI APS Model 3320) and a microorifice uniform 
deposit cascade impactor (MOUDI, MSP Corp., Minneapolis, MN). 
 
 
 
 
Tissue Collection 
At the termination of exposures, euthanasia (with CO2) was carried out in accordance with NIH guidelines. The 
brain areas of interest were dissected out and weighed, and then placed in high-purity linear polyethylene vials, 
frozen in liquid nitrogen, and stored at –70°C until analysis. 
 
RNA Isolation and Northern Blot Analysis 
The RNA tissue samples were homogenized and total RNA was extracted with a monophase phenol and 
guanidine isothiocyanate solution (RNA STAT-60; Tel-Test, Inc., Friendswood, TX). For Northern blot 
analysis, 10 μg of RNA was electrophoresed on a 1.2% agarose denaturing gel and transferred onto a positively 
charged nylon membrane (Nytran SuPer-Charge; Schleicher & Schuell, Keene, NH) overnight by capillary 
transfer in 10X SSC (1X SSC = 0.15 M sodium chloride, 0.015 M sodium citrate) buffer. The RNA was 
immobilized with a ultraviolet (UV) crosslinker. 
 
For MT or GS, the blots were prehybridized in 50% deionized for-mamide, 5X Denhardt’s solution, 10% 
dextran sulfate, 0.1% sodium dodecyl sulfate (SDS), 4X SSC 100 g/mL denatured salmon sperm DNA, 20 mM 
Tris-HCl, pH 8.0, for 1 h at 45°C. To probe for MT or GS, the blot was pre-hybridized in Ultrasensitive 
Hybridization Buffer (Ambion, Inc., Austin, TX) at 45°C. The RNA blots were then hybridized overnight with 
105 cpm/mL of [α-32P]dCTP-labeled random primed cDNA probe (approx 1 x 10
8
 cpm/μg; RadPrime DNA 
Labeling System, Gibco-BRL, Life Technologies, Rockville, MD). Membranes were washed two to three times 
in 2X SSC/0.1% SDS at 45°C for 20 min and then exposed to Kodak Biomax MR film, at –80°C with 
intensifying screens for 24–36 h. The autoradiograms were quantified by densitometry scanning in conjunction 
with the TINA v2.09e computer program (Raytest USA, Inc., Wilmington, NC). To correct for total loaded 
RNA level, the blots were stripped in 0.1X SSC/0.1%SDS/40 mM Tris buffer and probed for 28s rRNA (25). 
 
Protein Isolation and Western Blot Analysis 
Tissue lysates were centrifuged for 10 min at 10,000g to remove cellular debris, and the protein content of the 
resultant supernatant was determined with the bicinchoninic acid method (Pierce Chemical, Rockford, IL). An 
aliquot of 100 μg of protein was concentrated from the imidazole lysis buffer by organic extraction. Sample 
volumes were brought up to 400 μL with water and an equal volume of methanol (400 μL) was added, followed 
by 100 μL of chloroform. Samples were vortexed for 20 s and centrifuged at 14,000g for 3 min. The upper layer 
was removed and discarded. An additional 300 gL of methanol was added to each sample and they were again 
vortexed and centrifuged. The supernatant was removed and the pellet was air-dried. Each pellet was then 
dissolved in 100 μL 2% SDS and heated to 65°C. 
 
Five microliters of 5X loading buffer (50% glycerol; 10% SDS, 0.25 M Tris-HCl, pH 6.8) and dithiothreitol 
(DTT) (final concentration 100 mM) was added to the extracted proteins and the samples were boiled for 10 
min. Bromophenol blue (1 μL of a 50% [w/v] solution) was added and proteins were resolved by denaturing 
SDS-PAGE (polyacrylamide gel electrophoresis) with a 5% stacking and 8% resolving acrylamide gels in a 
0.1% SDS, 25 mM Tris-HCl, 192 mM glycine buffer. Following fractionation, proteins were electrophoretically 
transferred to a nitrocellulose membrane (Protran, BA83; Schleicher & Schuell, Keene, NH) in 20% methanol, 
0.1% SDS, 25 mM Tris-HCl, and 192 mM glycine for 3 h at 60 V. 
 
Membranes were blocked with 5% low-fat powdered milk in Tris-buffered saline with Tween (TBST; 0.1% 
Tween, 150 mM NaCl, 20 mM Tris-HCl) containing 0.1% gelatin (type B from bovine skin, Sigma, St. Louis, 
MO). GS proteins were detected with a monoclonal antibody (Chemicon, Temec-ula, CA) diluted to 1 : 2000 
followed by incubation with a horseradish-peroxidase-conjugated secondary antibody diluted to 1 : 2000 
(Kirkegaard and Perry Laboratories, Gaithersburg, MD), both in TBST and 5% milk for 1 h. Protein bands were 
visualized with the Renaissance enhanced chemiluminescence system (New England Nuclear, Boston, MA). 
The autoradiograms were quantified by densitometry scanning in conjunction with the TINA v2.09e computer 
program (Raytest USA, Inc., Wilmington, NC). 
 
 
GSH Level Determination 
Tissue samples (50–100 mg) were homogenized in 1 mL of 10% (v/v) perchloric acid containing 1 mM 
bathophenanthroline disulfonic acid (BPDS) and L-γ-glutamyl-L-glutamate. The mixture was vortexed and 
centrifuged, and an aliquot was removed for high-performance liquid chromatographic (HPLC) analysis (26) 
with a Waters model 600E multisolvent delivery system using an ion-exchange method with a methanol–acetate 
mobile phase and gradient elution. The limit of GSH detection was approx 50 pmol, which equated to approx 
0.4 nmol/mg protein (27,28). 
 
Statistical Analysis 
To determine statistical significance between experimental groups, one-way analysis of variance (ANOVA) was 
used. When the overall significance resulted in rejection of the null hypothesis (p < 0.05), the source of the 
variance was determined with the Student–Newman–Keuls posttest. All analyses were performed using 
GraphPad InStat version 3.02 for Windows (GraphPad Software, San Diego, CA). Unless otherwise noted, all 
data are presented as mean ± SEM values. 
 
RESULTS 
GS Protein and mRNA Expression 
A statistically significant (p<0.05) increase in GS protein was observed in rats’ olfactory bulbs at the medium 
(0.3 mg/m
3
) and high (3 mg/m
3
) doses of manganese (see Table 1). There was also a modest, but statistically 
significant (p<0.05) increase in GS in the hypothalamus at all doses. GS protein levels were significantly 
decreased in cerebellum at the highest manganese dose, despite a significant increase in the GS mRNA (see 
Table 1). 
Table 1  
GS Protein and mRNA Levels
a
 
 
Note: Values represent percentage of control mean ± SEM. 
* p< 0.05 versus respective controls. 
a
Given degradation in the tissue, MT mRNA levels in olfactory bulb or striatum could not be determined. 
Table 2  
Total GSH Levels 
 
Note: Values represent percentage of control mean ± SEM except where otherwise indicated. * p< 0.05 
versus respective controls 
Tyrosine hydroxylase protein levels were also evaluated in the striatum and olfactory bulb, but no significant 
differences were found (data not shown). 
 
GSH Levels 
The only brain region with a statistically significant (p<0.05) change in GSH levels was the hypothalamus (see 
Table 2). There was a 30% decrease in total GSH levels at the lowest dose, 50% decrease at the medium dose, 
and 75% decrease at the highest dose in the hypothalamus of manganese exposed as compared to control rats 
(see Table 2). However, only the 3- mg/m
3
 dose was statistically significant when compared to controls. 
 
MT mRNA Levels 
The hypothalamus was the only region in which the 0.3-mg/m
3
 manganese dose yielded (threefold) a 
statistically significant (p<0.05) increase in MT mRNA. Other regions had decreased MT mRNA because of 
manganese exposure, but these were not statistically significant, and they should be viewed with caution given 
the large variability (see Table 3). 
Table 3  
MT mRNA Levels
a 
 
Note: Values represent percentage of control mean ± SEM. 
* p< 0.05 versus respective controls 
a
 Given degradation in the tissue, MT mRNA levels in olfactory bulb or striatum could not be determined. 
 
DISCUSSION 
The current inhalation reference concentration for manganese, as set by the United States Environmental 
Protection Agency, is 0.05 μg Mn/m
3
. Thus, the concentrations of manganese used in this study were 600, 6000, 
and 60,000 times this standard for the low, medium, and high doses, respectively. The accumulation of 
manganese in three brain regions from exposed rats was assessed, and the relative concentrations were olfactory 
bulb > striatum > cerebellum (7). The control concentration of manganese in olfactory bulb was less than 1 μg/g 
tissue, and upon exposure to the highest manganese dose, it increased to almost 4.5 μg/g. Striatal differences 
were similar, with less than 1 μg/g in control animals and approx 3.25 μg/g tissue in animals receiving the 
highest manganese exposure. The cerebellar concentrations of manganese did not change upon manganese 
exposure (7), and the hypothalamic and hippocampal manganese levels were not analyzed. 
 
Oxidative stress can be measured through detection of many different chemical species. Some methods, such as 
direct detection by the fluorescence-producing reaction of dichlorofluorescein (DCF) with oxygen radicals can 
provide useful information in any type of tissue. Ali et al. (13) demonstrated that both manganese injected in 
vivo and exposure of brain regions to manganese in vitro resulted in detection of ROS by DCF fluorescence. 
The limitation of this technique is that living cells are required for study. Another rationale behind quantitation 
of oxidative stress is measurement of products directly damaged by the ROS. This damage can be found in 
every class of macromolecule, but DNA, lipid, and protein oxidation are most often investigated. The 
techniques for detection of these molecules are varied, and the inconsistency between methods has been widely 
debated. Artifactual formation of damage during sample preparation is one issue that may contribute to this 
problem. 
 
Another approach to detecting the presence of oxidants is to measure species that are known to increase or 
decrease in response to such stress. This includes ubiquitous antioxidants, such as glutathione, as well as ones 
that are more specific to particular tissue types or oxidative agents. In the CNS, GS is localized exclusively in 
astrocytes (29), where it has a critical role in amino acid metabolism. GS metabolizes glutamate that is removed 
from the extracellular space by astrocytes to glutamine, and the latter is recycled to neurons as part of the 
glutamate–glutamine cycle (30). GS is highly susceptible to oxidation and subsequent rapid degradation, and, 
therefore, it serves as an excellent marker for the presence of reactive oxy-gen species in the brain (31). The 
results of this study showed that GS protein levels increased considerably in olfactory bulb and to a lesser extent 
in hypothalamus (see Table 1). This may suggest lowered availability of glutamine for neuronal use as a with 
neurotransmitter homeostasis within these regions. However, one GS molecule requires eight manganese ions 
for optimal activity (32). Therefore, slight increases in manganese concentrations also enhance the activity of 
GS (33). It is possible that the elevated manganese levels also stimulate additional GS synthesis. No changes in 
GS protein levels were noted in the striatum, even though manganese accumulation was high following the 
inhalation exposures. 
 
The MTs are a class of highly conserved proteins, which are classically known to be upregulated in response to 
metal exposure. They contain cysteine and are known to bind metals, but in recent years, evidence has shown 
that they may also have some important antioxidant properties. Hainut and Milner (34) suggested that MTs can 
neutralize ROS through oxidative release of zinc from MT thiolate clusters. There is good evidence of MT 
upregulation in response to hyperoxia in the lung (35). In vitro experiments on the ability of several 
sulfhydrylcontaining molecules to scavenge oxygen radicals demonstrated that MTs are superior to others (36). 
Furthermore, Zhou et al. (37) found that MT-overexpressing transgenic mice were less susceptible to alcohol-
induced oxidative liver injury. Also, when two different mitochondrial-specific ROS generators were applied to 
cultured cells, MTs increased more than GSH, Mn-SOD (super-oxide dismutase) catalase, and other well-
known antioxidants (38). This study found that MT mRNA was increased in hypothalamus, where we also 
noted an increase in GS protein and a decrease in GSH (see Table 2). 
 
The data presented in these studies suggest that the olfactory bulb, previously found to have the highest 
accumulation of manganese after inhalation exposure (7), had the most changes in biochemical end points. This 
was not the case in the striatum, where there was a threefold increase in manganese concentration as a result of 
inhalation exposure, but no indication of oxidative stress (7). The hypothalamus, for which manganese lev-els 
after inhalation exposures were not measured, was observed to have changes in all of the oxidant indicators we 
analyzed. 
 
In summary, the present study determined whether oxidative stress could occur in the rat brain following 
inhalation of the sulfate form. The preliminary results indicate significant changes in the levels of GS protein in 
the olfactory bulb and hypothalamus upon exposure to the medium and high manganese doses. GSH levels 
decreased and MT mRNA increased in the hypothalamus (medium manganese dose), and there were no 
apparent changes in striatal tissue in any of the measured parameters. Given that the hypothalamus does not 
represent a target area for manganese toxicity in primates (39), it cannot be unequivocally stated at this point 
that our data support the ability of manganese to induce oxidative stress in this area. The effect of manganese on 
oxidative-stress-related end points (GSH content and GS) in the olfactory bulb is consistent with recent 
observations on the prominence of the olfactory pathway in manganese delivery to the brain in the rodent (40–
42), but given the interspecies differences in nasal and brain anatomy and physiology and the uncertainty about 
the role of olfactory pathways in the absorption of manganese in humans, the relevance of this finding to 
primates has yet to be determined. Finally, the lack of changes in any of the measured parameters in the 
striatum indicates that manganese inhalation, even at very high doses, does not induce oxidative stress in this 
brain region. 
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